Biotechnology firm Amgen announced a joint venture with pharmaceutical company Servier in a deal that gives Amgen the rights to heart drug ivabradine, approved in Europe, in the US. In return, Servier gained EU commercialization rights to a drug developed by Amgen, which has reached phase II testing in the US. The waiting period for antitrust regulators to review the deal has passed, say reports. Under terms of the joint venture, Amgen has the rights to chronic heart failure drug ivabradine, under the brand name in Europe of Procorain and will pay Servier $50 million for the rights. Additional financial details were not disclosed.
Full Content: PharmaTimes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI